Notably, studies have demonstrated that administering anti-FGF23 treatment can ameliorate hypophosphatemia and rickets in young mice with X-linked hypophosphatemia (XLH), while also increasing muscle strength and spontaneous motor activity in adult XLH mice [179]. The gene discussed is FGF23; the disease is X-linked hypophosphatemia.